OR WAIT null SECS
November 15, 2017
The use of approved platform technologies can reduce the time and cost required to generate new vaccines.
November 10, 2017
The company expects to commercially launch the new vaccine in the US in the first quarter of 2018.
November 03, 2017
The Human Vaccines Project has created the Universal Influenza Vaccine Initiative, a research program that will aim to understand the human immune system’s role in the development of universal influenza vaccines.
October 27, 2017
The vaccine is approved for the prevention of shingles in adult patients aged 50 years and older.
October 26, 2017
Inovio has reported results from a study with non-human primates that showed 100% effectiveness with a DNA vaccine the company is developing with the US Army.
October 20, 2017
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
October 19, 2017
The two companies announced their collaboration for the production and development of cancer vaccines.
October 16, 2017
Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.
October 12, 2017
The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.